Biotechnology News

JUPITER, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...

CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the Committee for Medicinal Products for Human Use (CHMP) of...

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that its most recent patent family on the NanoZolid® production process, and hence achieved pharmaceutical products, has been granted in China. The...

Start einer Phase-1-Studie bei Patienten mit fortgeschrittenen soliden Tumoren im ersten Quartal 2022 geplant Ad hoc-Mitteilung gemäss Art. 53 KR Basel, 17. Dezember 2021 Die Basilea...

Phase 1 study in patients with advanced solid tumors planned to start in the first quarter of 2022 Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, December 17, 2021 Basilea...

Obtention de droits exclusifs pour un nouveau composé de stade précoce acquis auprès de Genoscience Pharma dans le cholangiocarcinome aux Etats-Unis, au Canada et en EuropeLancement d’un programme...

Exclusive rights for a novel early-stage asset acquired from Genoscience Pharma in cholangiocarcinoma in the United States, Canada and EuropePhase 2 clinical program expected to start in 1H...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...

GENFIT : Ipsen et GENFIT concluent un accord de licence exclusif pour elafibranor, un composé évalué en Phase III dans la cholangite biliaire primitive, dans le cadre d’un partenariat global de long...

GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership ...